References
- Butenandt A, Hanisch G. Uber testosterone. Umwandlung des Dehydro-Androsterons in Androstendiol und Testosteron; ein Weg zur Darstellung des Testosterons aus Cholestrin. Hoppe Seylers Z Physiol Chem 1935;237:89
- Greenblatt RB. Testosterone propionate pellet implantation in genecic disorders. JAMA 1943;121:17–24
- Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483–9
- Hallberg O, Nohrman B, Sylven B. Survival time in women with disseminated breast cancer, following testosterone treatment. Acta Radiol 1953;39:161–8
- Rieche K, Wolff G. Comparison of testosterone decanoate, drostanolone and testololactone in disseminated breast cancer–a randomized clinical study. Arch Geschwulstforsch 1975;45:485–8
- Glaser RL, Dimitrakakis C. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. Maturitas 2013;76:342–9
- Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril 2017;107:475–482.e15
- Islam MR, Bell RJ, Green S, Page M, Davis SR. Efficacy and safety of testosterone therapy for women: a systematic review and meta-analysis of randomized controlled trails. Lancet Diabetes Endocrinol 2019 July 25. Epub ahead of print